Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Lorenzo, Giuseppe Di; Sonpavde, Guru; Pond, Gregory R.; Lucarelli, Giuseppe; Rossetti, Sabrina; Scagliarini, Sarah; Cartenì, Giacomo; Federico, Piera; Daniele, Bruno; Morelli, Franco; Bellelli, Teresa; Ferro, Matteo; Placido, Sabino De; Buonerba, Carlo

doi:10.1016/j.euf.2017.03.015

Cited by 25 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 66 articles were excluded after the review of abstracts, and 35 studies were potentially eligible and evaluated in detail. Overall, nine studies with 101 773 patients were identified that were eligible for inclusion in the meta‐analysis . Specifically, three studies were related to abiraterone or enzalutamide, whereas the rest six articles were about ADT .…”

Section: Resultsmentioning

confidence: 99%

“…However, another meta‐analysis demonstrated that such a potentially beneficial effect of statins on PCa was only found in the patients receiving radiotherapy, but not in those who accepted radical prostatectomy . Intuitively, whether the effect of statins on PCa could vary along with treatment modality arouses increasing attention in clinical practice …”

Section: Introductionmentioning

confidence: 99%

“…Newer agents, including abiraterone and enzalutamide, have been approved to manage patients with metastatic castration‐resistant prostate cancer (mCRPC) . Although a handful of studies about the influence of statins on treatment outcomes in PCa patients who were treated with ADT or abiraterone/enzalutamide have been published, results are inconsistent and vary by studies. Considering that the combination of statins and ADT for PCa could possibly generate additional impacts on the overall treatment outcomes, investigations focusing on the most appropriate target patient population are of great clinical importance to optimize treatment responses and improve the quality of life in PCa patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

Yang

Pang

et al. 2020

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective: To evaluate the effects of statin use on the treatment outcomes (i.e. overall survival and cancer-specific survival) among advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) or abiraterone/enzalutamide. Methods: The original studies, examining the effects of statins on the outcomes (i.e. overall survival and cancer-specific survival) among PCa patients treated with ADT or abiraterone/enzalutamide, were identified through a systematic search by two independent reviewers in the PubMed, Cochrane, Embase, American Society of Clinical Oncology and European Society of Medical Oncology databases. Databases were searched using keywords (abiraterone OR enzalutamide OR androgen deprivation therapy) AND statin. In total, nine eligible studies from 111 references were included for final analysis.Results and discussion: Statin use significantly lowered the risk of all-cause mortality (100 709 patients, HR = 0.73, 95%CI = 0.64-0.83, P < .00001) and the risk of cancerspecific mortality (100 343 patients, HR = 0.64, 95% CI = 0.53-0.77, P < .00001) in advanced PCa patients treated with ADT. The sensitivity analysis showed that the results were reliable. However, it could not generate reliable evidence in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone/ enzalutamide, as relevant studies were limited and had inconsistent results.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

Yang

Pang

et al. 2020

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…ARSi drives changes in metabolic profiles and body composition. Previous studies demonstrate relationships between ARSi therapy and lipid metabolism and statin use (23)(24)(25). Both abiraterone and enzalutamide can induce increases in body fat mass and decreases in lean body mass (26,27).…”

Section: Discussionmentioning

confidence: 97%

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Objectives: The association of body composition with survival and the efficacy of first-line treatment was investigated in patients with castration-resistant prostate cancer (CRPC). Methods: The records of CRPC patients treated with docetaxel or androgen receptor signaling inhibitors (ARSi) between 2005 and 2018 were reviewed. Skeletal muscle index (SMI), visceral fat index, and subcutaneous fat index were evaluated using pretreatment computed tomography images. Results: Of 230 eligible patients, 144 received docetaxel, and 86 received ARSi as the first-line treatment for CRPC. The SMI hi (based on median values) group had higher prostate-specific antigen (PSA) progression-free survival (median 13.5 vs. 8.3 months, p = 0.030), radiologic progression-free survival (14.9 vs. 9.1 months, p < 0.001), and overall survival (24.1 vs. 16.9 months, p = 0.015) than the SMI lo group. In docetaxel-treated patients, the SMI hi group had higher PSA progression-free survival (13.5 vs. 5.9 months, p = 0.016) and radiologic progression-free survival (14.6 vs. 6.7 months, p < 0.001) than the SMI lo group. However, PSA progression-free survival and radiologic progression-free survival were comparable between the two groups in ARSi-treated patients. SMI was independently associated with the risk of radiologic progression in patients treated with docetaxel but not in those treated with ARSi. Conclusions: High skeletal muscle mass may be associated with reduced risk of disease progression and mortality in patients with CRPC. However, the significance of these relationships is limited in patients treated with docetaxel. These results suggest that assessing skeletal muscle mass may be worthwhile when selecting treatments for CRPC; however, further prospective validation and large-scale studies are needed.

show abstract

“…Although these relationships still remain controversial, hypercholesterolemia is reported to be associated with a shorter time to castration-resistant PCa (CRPC) after ADT and survival after treatment for CRPC. 9 10 From the viewpoint of not only cardiovascular risk but also cancer management, it seems to be very important to aggressively manage dyslipidemia with the use of statins after initiation of ADT in patients with PCa.…”

mentioning

confidence: 99%

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy

Oka

2018

Asian J Androl

View full text Add to dashboard Cite

Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Cited by 25 publications

References 32 publications

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta‐analysis

Association of Body Composition With Survival and Treatment Efficacy in Castration-Resistant Prostate Cancer

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy

Contact Info

Product

Resources

About